How to buy Cytokinetics Incorporated stock | $35.73

Cytokinetics Incorporated is a biotechnology business based in the US. Cytokinetics Incorporated shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Cytokinetics Incorporated employs 184 staff and has a trailing 12-month revenue of around 0.00.

Cytokinetics Incorporated stock price (NASDAQ: CYTK)

Use our graph to track the performance of CYTK stocks over time.

Cytokinetics Incorporated shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$35.73
52-week range	$14.89 - $39.46
50-day moving average	$34.27
200-day moving average	$27.34
Wall St. target price	$50.36
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.21

Buy Cytokinetics Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cytokinetics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytokinetics Incorporated price performance over time

Historical closes compared with the close of $35.73 from 2021-10-20

1 week (2021-10-14)	-6.29%
1 month (2021-09-22)	5.59%
3 months (2021-07-22)	18.70%
6 months (2021-04-22)	37.42%

1 year (2020-10-21)	127.58%
2 years (2019-10-21)	214.52%
3 years (2018-10-19)	392.15%
5 years (2016-10-21)	288.79%

Cytokinetics Incorporated financials

Revenue TTM	$57.8 million
Gross profit TTM	$-41,123,000
Return on assets TTM	-19.87%
Return on equity TTM	-1219.69%
Profit margin	-269.48%
Book value	$0.23
Market capitalisation	$3.1 billion

TTM: trailing 12 months

Shorting Cytokinetics Incorporated shares

There are currently 10.5 million Cytokinetics Incorporated shares held short by investors – that's known as Cytokinetics Incorporated's "short interest". This figure is 1.8% down from 10.7 million last month.

There are a few different ways that this level of interest in shorting Cytokinetics Incorporated shares can be evaluated.

Cytokinetics Incorporated's "short interest ratio" (SIR)

Cytokinetics Incorporated's "short interest ratio" (SIR) is the quantity of Cytokinetics Incorporated shares currently shorted divided by the average quantity of Cytokinetics Incorporated shares traded daily (recently around 945088.65886589). Cytokinetics Incorporated's SIR currently stands at 11.11. In other words for every 100,000 Cytokinetics Incorporated shares traded daily on the market, roughly 11110 shares are currently held short.

However Cytokinetics Incorporated's short interest can also be evaluated against the total number of Cytokinetics Incorporated shares, or, against the total number of tradable Cytokinetics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytokinetics Incorporated's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Cytokinetics Incorporated shares in existence, roughly 130 shares are currently held short) or 0.1265% of the tradable shares (for every 100,000 tradable Cytokinetics Incorporated shares, roughly 127 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cytokinetics Incorporated.

Find out more about how you can short Cytokinetics Incorporated stock.

Cytokinetics Incorporated share dividends

We're not expecting Cytokinetics Incorporated to pay a dividend over the next 12 months.

Have Cytokinetics Incorporated's shares ever split?

Cytokinetics Incorporated's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics Incorporated shares which in turn could have impacted Cytokinetics Incorporated's share price.

Cytokinetics Incorporated share price volatility

Over the last 12 months, Cytokinetics Incorporated's shares have ranged in value from as little as $14.8901 up to $39.46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics Incorporated's is 1.3101. This would suggest that Cytokinetics Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cytokinetics Incorporated overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Frequently asked questions

What percentage of Cytokinetics Incorporated is owned by insiders or institutions?
Currently 4.737% of Cytokinetics Incorporated shares are held by insiders and 94.888% by institutions. How many people work for Cytokinetics Incorporated?
Latest data suggests 184 work at Cytokinetics Incorporated. When does the fiscal year end for Cytokinetics Incorporated?
Cytokinetics Incorporated's fiscal year ends in December. Where is Cytokinetics Incorporated based?
Cytokinetics Incorporated's address is: 280 East Grand Avenue, South San Francisco, CA, United States, 94080 What is Cytokinetics Incorporated's ISIN number?
Cytokinetics Incorporated's international securities identification number is: US23282W6057 What is Cytokinetics Incorporated's CUSIP number?
Cytokinetics Incorporated's Committee on Uniform Securities Identification Procedures number is: 23282W100